IMPL - Impel NeuroPharma GAAP EPS of -$1.09 misses by $0.04 revenue of $2.8M misses by $1.04M August, 15 2022 08:13 AM Impel Pharmaceuticals Inc. Impel NeuroPharma press release ( NASDAQ: IMPL ): Q2 GAAP EPS of -$1.09 misses by $0.04 . Revenue of $2.8M misses by $1.04M . For further details see: Impel NeuroPharma GAAP EPS of -$1.09 misses by $0.04, revenue of $2.8M misses by $1.04M